[company_age]7.0[/company_age][employees]2-10 employees[/employees][funding]Seed[/funding][description]ReceptorPharma is a pharmaceutical company that is developing a new drug to treat Alzheimer's disease. The company's drug, RP301, is based on a novel approach that targets a recently discovered signaling pathway. This approach is different from other Alzheimer's drugs that only treat the symptoms of the disease. ReceptorPharma believes that RP301 has the potential to be a blockbuster drug and is seeking funding to complete the development of the drug.[/description][ps]RP301, a drug for Alzheimer's disease.[/ps]